Abstract
Pharmaco‐economic evaluations become more important for the reimbursement of pharmaceuticals, and will be obligatory for new pharmaceutical drugs for which an added therapeutic value is claimed and a price premium is proposed by the manufacturer. Therefore, it is important to guide purchasers and providers of pharmaceutical care in their efforts related to the evaluation process. Standard Report Format can support the quality, transparency and exhaustiveness of the data submitted. A multidisciplinary task force developed a Standard Report Format for pharmaco‐economic evaluations in Belgium.
This is a preview of subscription content, log in via an institution to check access.
References
Developing Guidance for Budget Impact Analysis. Trueman P, Drummond M. and Hutton J. Pharmacoeconomics 2001;19 (6):609–21.
Projet de loi porte des mesures en matière de soins de santé-Wetsontwerp houdende maatregelen inzake Gezondheidszorg.-Belgisch Staatsblad-Monétaire Belge Sept 1, 2001.
The Revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals. Pharmacoeconomics 1999,15(5):459-68
Reporting format for economic evaluation. Nuijten M.Sc., Brorens M.J.A., Helster Y.A. et al. Pharmacoeconomics 1998,14(2):159–63.
A proposal for methodological quidelines for economic evaluations of pharmaceutical. Bespe. November 1995.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Annemans, L., Crott, R., Degraeve, D. et al. Recommended structure for reporting economic evaluation on pharmaceuticals in Belgium. Pharm World Sci 24, 5–7 (2002). https://doi.org/10.1023/A:1014896830042
Issue Date:
DOI: https://doi.org/10.1023/A:1014896830042